ISRCTN83465351 https://doi.org/10.1186/ISRCTN83465351

L-CARnitine in the palliative treatment of advanced PANcreatic cancer (CARPAN)

Submission date	Recruitment status	[ ] Prospectively registered
24/03/2011	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
12/04/2011	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
17/05/2011	Cancer	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Markus Lerch

Contact details
Department of Medicine A
University Medicine Greifswald
Friedrich Löffler Straße 23a
Greifswald
Germany
17475

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
L-Carnitine in the palliative treatment of advanced pancreatic cancer (CARPAN): a prospective, randomised, placebo controlled, double blinded, multicentre trial

Acronym

CARPAN

Study objectives
The study investigated the role of L-Carnitine supplementation on proinflammatory immune response, malnutrition, cancer cachexia and cancer related fatigue in advanced and inoperable pancreatic cancer, International Union Against Cancer Classification (UICC) Stage IV .

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethics Commission for the Medical Faculty of the University of Greifswald approved on 30.11.2005, ref no: UV 73/05

Study design
Placebo controlled double blinded randomised prospective multicentre study

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Advanced pancreatic cancer

Interventions
Intervention (Verum): L-Carnitine 4 g/day
Placebo: Tartaric acid
Both administered orally

The trial duration was 3 month, patient visit at time of enrolment, week 6 and week 12

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
L-Carnitine

Primary outcome(s)
Influence of L-Carnitine on proinflammatory cytokine tumor necrosis factor (TNF)-alpha

Key secondary outcome(s))
1. Influence of L-Carnitine on
1.1. Other proinflammatory cytokines (IL 6, IL8, IL12)
1.2. C-reactive protein (CRP)

1.3. Malnutrition and cancer cachexia, cancer related fatigue syndrome
1.4. Mortality
1.5. Hospital stay

Completion date
31/10/2009

Eligibility

Key inclusion criteria
1. Advanced pancreatic cancer (UICC Stage IV)
2. A Karnofsky Index larger than 60
3. Compliance
4. The consent to participate in the study

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
1. Patients were excluded with a Child-Pugh classification of liver failure greater than Class B
2. A known second malignant tumor
3. Oral or parenteral supplementation with omega-3-fatty acids
4. Treatment with Thalidomide or Infliximab
5. Mental or physical disorders

Date of first enrolment
01/06/2006

Date of final enrolment
31/10/2009

Locations

Countries of recruitment
Germany

Study participating centre
Department of Medicine A
Greifswald

Germany
17475

Sponsor information

Organisation
University Medicine Greifswald (Germany)

ROR
https://ror.org/00r1edq15

Funder(s)

Funder type
University/education

Funder Name
University Medicine Greifswald (Germany) - Department of Medicine A

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration